Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

re preclinical spend

I'm reading the 10k now, and I find it curious that the spend on Kit was higher in the comparable quarter last year when they were in the thick of lead optimization versus IND-enabling, and also that the spend on stat6 now (lead optimization) is a tad higher than KIT (scale up and IND)
It's usually the reverse where preclinical costs accelerate once you head into IND-enabling stage. The relative cost per se is trivial in the scheme of things, but just an observation that ENTA seems to really put resources into that "apple polishing" as Jay Luly likes to call it